uniQure Receives 2017 Frost & Sullivan Manufacturing Leadership Award

19:00 EST 2 Mar 2017 | Globe Newswire

-- Lexington, MA-based Gene Therapy Facility Recognized for Enabling Manufacturing Excellence --

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 03, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that it has been recognized by Frost & Sullivan as a 2017 Manufacturing Leadership Awards winner for outstanding achievement in Engineering & Production Technology Leadership related to its Lexington, Massachusetts gene therapy manufacturing facility. 

uniQure’s Lexington-based facility is one of the largest, most versatile gene therapy manufacturing facilities in the world.  Over the past four years, uniQure has invested more than $25 million in designing, constructing and equipping its 55,000 square foot facility with state-of-the-art laboratories and commercial-scale production capabilities. The facility offers 500-liter capacity with the ability to expand to up to 2,000 liters when needed. 

“The innovative design of our facility, which incorporated 3D modeling and single-use components, required substantially less upfront capital expenditures and enables us to operate at significantly lower costs compared to other production systems,” stated Lance Weed, vice president of operations for uniQure. “Our use of disposable components in our manufacturing process reduces the need for maintenance and testing, lowers the risk of contamination, enables rapid product changeovers, and requires substantially less personnel to operate.” 

“uniQure is committed to manufacturing excellence in gene therapy and we are delighted that Frost & Sullivan has recognized our achievements in this regard,” stated Matt Kapusta, chief executive officer of uniQure.  “We continue to believe that our leading manufacturing capabilities provide us a significant competitive advantage in rapidly delivering gene therapies to patients, including our lead product candidate in hemophilia B, for which we plan to begin a global pivotal study in 2018.” 

uniQure will be recognized at the 13th Annual Manufacturing Leadership Awards Gala, which is to be held on the last day of the Manufacturing Leadership Summit, June 12-14, 2017 at the Hyatt Regency Huntington Beach Resort and Spa in Huntington Beach, CA.

Additional Resources

About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases.

About the Frost & Sullivan Manufacturing Leadership Awards
The Frost & Sullivan Manufacturing Leadership Awards, now in their 13th year, honor manufacturing companies and individual manufacturing leaders that are shaping the future of global manufacturing. Winning projects and individual manufacturing leaders have demonstrated achievement in one of a wide range of categories, and are chosen by a panel of expert judges for results that have delivered clear and compelling value, return on investment, and other tangible outcomes. There will be several winners in each category, including one High Achiever’s Award in each category, as well as a 2017 Manufacturer of the Year for both small and large enterprises. Also unveiled at the Gala will be the ML Awards Manufacturing Leader of the Year and Lifetime Achievement Award winners.

The theme for the 13th Annual Manufacturing Leadership Summit is “Manufacturing 4.0 in Action.” The event enables senior-level executives in all aspects of manufacturing an opportunity to network with and learn from the best minds in the industry

For more information on the Manufacturing Leadership Awards or the Manufacturing Leadership Summit, please go to

uniQure Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the implementation and effects of the Company’s new strategic and organizational changes, the development of our gene therapy product candidates, the success of our collaborations and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with corporate reorganizations and strategic shifts, collaboration arrangements, our and our collaborators’ clinical development activities, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure’s 2015 Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2016. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts:

Maria E. Cantor		
Direct: 339-970-7536	
Mobile:  617-680-9452 	

Eva M. Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79 

Tom Malone
Direct:  339-970-7558
Mobile:  339-223-8541

Primary Logo


More From BioPortfolio on "uniQure Receives 2017 Frost & Sullivan Manufacturing Leadership Award"

Quick Search


Relevant Topics

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Antiretroviral therapy
Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering whe...